A61P 13 - Drugs for disorders of the urinary system

Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
11/2004
11/04/2004	US20040220204 mixture of fatty ester, alkylene carbonate, butylene glycol, diethylene glycol, monoalkyl ether and thickeners
11/04/2004	US20040220133 Composition and method for inhibiting platelet aggregation
11/04/2004	US20040220092 G-protein coupled receptors
11/04/2004	US20040219633 Method of producing recombinant antibodies
11/04/2004	US20040219202 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety
11/04/2004	US20040219176 dosage form of a mixture of drugs, foaming agents and gases, having improved pharmacokinetics; drug delivery systems
11/04/2004	CA2563312A1 Plasmid mediated ghrh supplementation for renal failures
11/04/2004	CA2522300A1 Treatment of angiotensin ii related disease
11/03/2004	EP1473303A1 Novel proteins and dnas thereof
11/03/2004	EP1473295A1 Fused bicyclic pyrimidine derivatives
11/03/2004	EP1473288A1 Nitric ester derivatives of COX-2 inhibitors and their use for treating inflammation and cardiovascular diseases
11/03/2004	EP1472544A2 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/03/2004	EP1472377A2 Genetic polymorphisms in the preprotachykinin gene
11/03/2004	EP1472376A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
11/03/2004	EP1472273A2 Compositions and methods for the treatement of immune related diseases
11/03/2004	EP1472269A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/03/2004	EP1472267A2 Rna interference mediated inhibition of protein tyrosine phosphatase type iva (prl3) gene expression using short interfering nucleic acid (sina)
11/03/2004	EP1472257A1 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
11/03/2004	EP1472251A1 Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
11/03/2004	EP1472250A1 Anticholinergic agents, method for producing the same and use thereof as medicaments
11/03/2004	EP1472249A1 Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments
11/03/2004	EP1472243A1 Piperidine derivatives and their use as antagonists of tachykinins
11/03/2004	EP1472241A1 Cytoprotective benzofuran derivatives
11/03/2004	EP1472237A1 Catechol bioisosteres
11/03/2004	EP1472231A1 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
11/03/2004	EP1472225A2 2-piperazine-pyridines useful for treating pain
11/03/2004	EP1472224A2 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/03/2004	EP1472221A2 Substituted indoles, method for production and use thereof for the inhibition of pain
11/03/2004	EP1472209A2 Lipoxin a4 analogs
11/03/2004	EP1471938A2 Human monoclonal antibodies against cd30
11/03/2004	EP1471927A2 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
11/03/2004	EP1471907A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases
11/03/2004	EP1471818A2 Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules
11/03/2004	EP1377550B1 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
11/03/2004	EP1339716B1 lactam-substituted pyrazolopyridine derivatives
11/03/2004	EP1337271B1 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
11/03/2004	EP1278547B1 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
11/03/2004	EP1261609B1 Triazolotriazinones and the use thereof
11/03/2004	EP1235814B1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
11/03/2004	EP1169338B1 Low-molecular inhibitors of complement proteases
11/03/2004	EP0877748B1 Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives, their preparation and use
11/03/2004	EP0788305B1 Composition for inactivating irritants in fluids
11/03/2004	CN1543456A Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
11/03/2004	CN1543352A Method and material for treating immune diseases
11/03/2004	CN1543344A Aryl(or hetero aryl) aza cyclopentadienyl carbinol ramifications for treating urinary incontinence
11/03/2004	CN1541695A Acute cystourethritis treating medicine
11/03/2004	CN1541684A Oral Chinese traditional medicine preparation for treating cystitis
11/03/2004	CN1173974C Piperidylaminomethyltrifluoromethyl cyclic ether compound as p substance antagonist
11/03/2004	CN1173964C Novel benzofuranone derivative and process for producing same
11/03/2004	CN1173735C Use of anti-gp 39 antibodies for treatment and/or reversal of lupus and associated kidney disease
11/03/2004	CN1173734C Health-care food for improving prostatoplasia
11/03/2004	CN1173732C Traditional Chinese medicine pills for skin and venereal disease and urinary system infection
11/03/2004	CN1173727C Chinese medicine liquor for clearing and activating main and collateral channels, and its preparation method
11/02/2004	US6812364 Central nervous system disorders; psychological disorders; anticancer agents
11/02/2004	US6812253 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical
11/02/2004	US6812250 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments
11/02/2004	US6812230 Pharmaceutical compositions useful in treating progressive renal fibrosis in mammals comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a non-peptide ccr1 receptor antagonist.
11/02/2004	US6812226 For therapy of rheumatoid arthritis, effecting immunosuppression
11/02/2004	US6812034 Diagnosing calcification of arteries; obtain blood sample, screen for the presence of fetuin-mineral complex in blood, amplified concentration of fetuin complex indicates calcification of arteries and other soft tissues
11/02/2004	CA2315614C Pyrazoles
11/02/2004	CA2296970C Neuropeptide y antagonists
11/02/2004	CA2296313C 2-aminopyridines containing fused ring substituents as nos inhibitors
10/2004
10/28/2004	WO2004092199A2 Method for identifying modulators of g protein coupled receptor signaling
10/28/2004	WO2004092179A1 Spiro derivative, production process, and antioxidant
10/28/2004	WO2004092169A1 Spiropiperidine compound and medicinal use thereof
10/28/2004	WO2004092163A1 Phenylazole compound, production process, and antioxidant drug
10/28/2004	WO2004092153A1 Diamine derivative, production process, and antioxidizing drug
10/28/2004	WO2004092136A1 Nitrogenous heterocyclic compound and use thereof
10/28/2004	WO2004091628A1 Receptor antagonist
10/28/2004	WO2004091607A1 Quaternary ammonium compounds and their use as antimuscarinic agents
10/28/2004	WO2004080444A3 Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
10/28/2004	WO2004078104A3 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
10/28/2004	WO2004072643A3 Diagnostics and therapeutics for diseases associated with glucagon-like peptide 2 receptor (glp2r)
10/28/2004	WO2004069806A3 Substituted 2-aminoimidazoles, method for the production thereof, their use as a medicament or as a diagnostic reagent, and medicament containing these compounds
10/28/2004	WO2004064716A3 Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders
10/28/2004	WO2004047838A3 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
10/28/2004	WO2003095613A3 Nucleic acids, polypeptides, and methods for modulating apoptosis
10/28/2004	WO2003077840A3 Method of modulating inflammatory response
10/28/2004	WO2001081540A3 Growth factor which acts through erb b-4 rtk
10/28/2004	WO2001039723A3 Triazospiro compounds having nociceptin receptor affinity
10/28/2004	US20040215181 Delivery of fluid during transurethral prostate treatment
10/28/2004	US20040215023 Crystal and process for producing the same
10/28/2004	US20040214996 Multimeric peptides/immunoglobulins for use in the treatment of bone disorders
10/28/2004	US20040214896 drugs and/or prodrugs such as N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide, used for prophylaxis of inflammatory disorders, cancers, psoriasis, diabetes, autoimmune diseases, hepatitis, graft versus host disease or endometriosis
10/28/2004	US20040214875 Imidazolinylmethyl aralkylsulfonamides
10/28/2004	US20040214874 Inhibition of protein-tyrosine kinase cmet to block cancer cell proliferation, oral bioavailibility; 2-(2,6-dichlorophenyl)-4-phenyl-5-(pyrimidin-4yl)-1H-imidazoles
10/28/2004	US20040214871 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester
10/28/2004	US20040214822 Substituted 4-aminocyclohexanol compounds
10/28/2004	US20040214814 Pyrazole compounds useful as protein kinase inhibitors
10/28/2004	US20040214759 Compositions and methods of use for a fibroblast growth factor
10/28/2004	US20040213845 comprises a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent
10/28/2004	US20040213797 Conjugates for the modulation of immune responses
10/28/2004	US20040213793 nucleic acid molecule encoding a transmembrane TEM1; Inhibiting neoangiogenesis by administering a molecule with an antibody variable region which specifically binds to an extracellular domain of a Tumor Endothelial Markers (TEMs) protein; polycystic kidney disease; psoriasis
10/28/2004	US20040213791 Monoclonal antibodies; for diagnosis and treatment of prostate cell proliferative disorders; immunogens; immunotherapy; cell lines
10/28/2004	DE10315702A1 Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis Using Arzneitmittelkombinationen for the treatment of benign prostatic hyperplasia or for the treatment of abacterial prostatitis
10/28/2004	CA2522266A1 Phenylazole compound, production process therefor and antioxidant
10/28/2004	CA2522102A1 Quaternary ammonium compounds and their use as antimuscarinic agents
10/28/2004	CA2522076A1 Method for identifying modulators of g protein coupled receptor signaling
10/27/2004	EP1471056A1 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
10/27/2004	EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these

1 ... 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 ... 562